Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

Lipids in Health and Disease

Volumn 7, Issue , 2008, Pages

  Mayne, Janice ^a   Dewpura, Thilina ^a   Raymond, Angela ^a   Cousins, Marion ^b   Chaplin, Anna ^b   Lahey, Karen A ^c   LaHaye, Stephen A ^c   Mbikay, Majambu ^a   Ooi, Teik Chye ^a,b   Chrétien, Michel ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; ENZYME VARIANT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLYCOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN LIKE 9; SIMVASTATIN; STATINE DERIVATIVE; CLOFIBRIC ACID; HEPTANOIC ACID DERIVATIVE; PCSK9 PROTEIN, HUMAN; PYRROLE DERIVATIVE; SERINE PROTEINASE;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; CELL STRAIN HEPG2; CORONARY ARTERY DISEASE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VIVO STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RECEPTOR UPREGULATION; TRANSCRIPTION REGULATION; BLOOD; CLINICAL TRIAL;

CLOFIBRIC ACID; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 45549096493     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-7-22     Document Type: Article

References (34)

1. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. NG Seidah S Benjannet L Wickham J Marcinkiewicz SB Jasmin S Stifani A Basak A Prat M Chretien, Proc Natl Acad Sci U S A 2003 100 3 928 933 12552133 10.1073/pnas.0335507100
2. [After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9.]. M Abifadel JP Rabes C Boileau M Varret, Ann Endocrinol (Paris) 2007 17391637
3. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. M Abifadel M Varret JP Rabes D Allard K Ouguerram M Devillers C Cruaud S Benjannet L Wickham D Erlich A Derre L Villeger M Farnier I Beucler E Bruckert J Chambaz B Chanu JM Lecerf G Luc P Moulin J Weissenbach A Prat M Krempf C Junien NG Seidah C Boileau, Nat Genet 2003 34 2 154 156 10.1038/ng1161 12730697
4. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. KM Timms S Wagner ME Samuels K Forbey H Goldfine S Jammulapati MH Skolnick PN Hopkins SC Hunt DM Shattuck, Hum Genet 2004 114 4 349 353 10.1007/s00439-003-1071-9 14727179
5. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. TP Leren, Clin Genet 2004 65 5 419 422 10.1111/j.0009-9163.2004.0238.x 15099351
6. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. SE Humphries RA Whittall CS Hubbart S Maplebeck JA Cooper AK Soutar R Naoumova GR Thompson M Seed PN Durrington JP Miller DJ Betteridge HA Neil, J Med Genet 2006 43 12 943 949 10.1136/jmg.2006.038356 17142622
7. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. J Cohen A Pertsemlidis IK Kotowski R Graham CK Garcia HH Hobbs, Nat Genet 2005 37 2 161 165 10.1038/ng1509 15654334
8. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy. KE Berge L Ose TP Leren, Arterioscler Thromb Vasc Biol 2006 26 5 1094 10.1161/01.ATV.0000204337.81286.1c 16424354
9. A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol. IK Kotowski A Pertsemlidis A Luke RS Cooper GL Vega JC Cohen HH Hobbs, Am J Hum Genet 2006 78 3 410 422 16465619 10.1086/500615
10. Biomedicine. Lowering LDL - not only how low, but how long? MS Brown JL Goldstein, Science 2006 311 5768 1721 1723 10.1126/science.1125884 16556829
11. Protease variants, LDL, and coronary heart disease. AR Tall, N Engl J Med 2006 354 12 1310 1312 10.1056/NEJMe068026 16554535
12. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. JD Horton NA Shah JA Warrington NN Anderson SW Park MS Brown JL Goldstein, Proc Natl Acad Sci U S A 2003 100 21 12027 12032 14512514 10.1073/pnas.1534923100
13. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. KN Maxwell RE Soccio EM Duncan E Sehayek JL Breslow, J Lipid Res 2003 44 11 2109 2119 10.1194/jlr.M300203-JLR200 12897189
14. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. G Dubuc A Chamberland H Wassef J Davignon NG Seidah L Bernier A Prat, Arterioscler Thromb Vasc Biol 2004 24 8 1454 1459 10.1161/01.ATV.0000134621.14315.43 15178557
15. Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL Cholesterol. WE Alborn G Cao HE Careskey YW Qian DR Subramaniam J Davies EM Conner RJ Konrad, Clin Chem 2007 53 10 1814 1819 10.1373/clinchem.2007.091280 17702855
16. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. TA Lagace DE Curtis R Garuti MC McNutt SW Park HB Prather NN Anderson YK Ho RE Hammer JD Horton, J Clin Invest 2006 116 11 2995 3005 17080197 10.1172/JCI29383
17. Plasma PCSK9 levels correlate with cholesterol in men but not in women. J Mayne A Raymond A Chaplin M Cousins N Kaefer C Gyamera-Acheampong NG Seidah M Mbikay M Chretien TC Ooi, Biochem Biophys Res Commun 2007 361 2 451 456 10.1016/j.bbrc.2007.07.029 17645871
18. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. D Cunningham DE Danley KF Geoghegan MC Griffor JL Hawkins TA Subashi AH Varghese MJ Ammirati JS Culp LR Hoth MN Mansour KM McGrath AP Seddon S Shenolikar KJ Stutzman-Engwall LC Warren D Xia X Qiu, Nat Struct Mol Biol 2007 17435765
19. The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR. N Nassoury DA Blasiole A Tebon Oler S Benjannet J Hamelin V Poupon PS McPherson AD Attie A Prat NG Seidah, Traffic 2007 17461796
20. Secreted proprotein convertase subtilisin/kexin-type 9 downregulates low-density lipoprotein receptor through receptor-mediated endocytosis. YW Qian RJ Schmidt Y Zhang S Chu A Lin H Wang X Wang TP Beyer WR Bensch W Li ME Ehsani D Lu RJ Konrad PI Eacho DE Moller SK Karathanasis G Cao, J Lipid Res 2007 17449864
21. Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation. DW Zhang TA Lagace R Garuti Z Zhao M McDonald JD Horton JC Cohen HH Hobbs, J Biol Chem 2007 282 25 18602 18612 10.1074/jbc.M702027200 17452316
22. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. S Benjannet D Rhainds R Essalmani J Mayne L Wickham W Jin MC Asselin J Hamelin M Varret D Allard M Trillard M Abifadel A Tebon AD Attie DJ Rader C Boileau L Brissette M Chretien A Prat NG Seidah, J Biol Chem 2004 279 47 48865 48875 10.1074/jbc.M409699200 15358785
23. Therapeutic roles of peroxisome proliferator-activated receptor agonists. B Staels JC Fruchart, Diabetes 2005 54 8 2460 2470 10.2337/diabetes.54.8.2460 16046315
24. Micronised fenifibrate or gemfibrozil in patients with combined hyperlipidemia: a double-blind randomized multicentre trial. AJC Dzavik V Delaval D., Atherosclerosis 1999 144(Suppl 1) 32 10.1016/S0021-9150(99)80119-1
25. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. JA Tobert, Nat Rev Drug Discov 2003 2 7 517 526 10.1038/nrd1112 12815379
26. Mechanism of action of fibrates on lipid and lipoprotein metabolism. B Staels J Dallongeville J Auwerx K Schoonjans E Leitersdorf JC Fruchart, Circulation 1998 98 19 2088 2093 9808609
27. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. S Kourimate C Le May C Langhi AL Jarnoux K Ouguerram Y Zair P Nguyen M Krempf B Cariou P Costet, J Biol Chem 2008 18245819
28. Study of Dose-linearity of gemfibrozil Pharmokinetics in Humans. MR Rouini Baluchestani, M and Hakemi, L., International Journal of Pharmacology 2006 2 1 75 78
29. Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers. C Harvengt JP Desager, Eur J Clin Pharmacol 1980 17 6 459 463 10.1007/BF00570164 7398737
30. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. M Amemiya-Kudo H Shimano AH Hasty N Yahagi T Yoshikawa T Matsuzaka H Okazaki Y Tamura Y Iizuka K Ohashi J Osuga K Harada T Gotoda R Sato S Kimura S Ishibashi N Yamada, J Lipid Res 2002 43 8 1220 1235 12177166
31. Expression and localization of PCSK9 in rat hepatic cells. PN Grozdanov PM Petkov LK Karagyozov MD Dabeva, Biochem Cell Biol 2006 84 1 80 92 10.1139/o05-155 16462892
32. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. P Costet B Cariou G Lambert F Lalanne B Lardeux AL Jarnoux A Grefhorst B Staels M Krempf, J Biol Chem 2006 281 10 6211 6218 10.1074/jbc.M508582200 16407292
33. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. HE Careskey RA Davis WE Alborn JS Troutt G Cao RJ Konrad, J Lipid Res 2008 49 2 394 398 10.1194/jlr.M700437-JLR200 18033751
34. Generation of high titer antisera in rabbits by DNA immunization. PS Chowdhury M Gallo I Pastan, J Immunol Methods 2001 249 1-2 147 154 10.1016/S0022-1759(00)00353-7 11226472